Tvardi Therapeutics, Inc.

As of June 30, 2026, Tvardi Therapeutics Inc. carries a market capitalization of 15.29M, placing it among publicly traded companies globally. Its enterprise value stands at 1.62M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Tvardi Therapeutics Inc.'s next confirmed earnings release is scheduled for November 12, 2026.

As of June 30, 2026, Tvardi Therapeutics Inc. has 9.38M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Tvardi Therapeutics Inc. maintains a current ratio of 1.87, meaning it holds 1.9x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, Tvardi Therapeutics Inc. posted a negative return on equity (ROE) of -126.19, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -85.08, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 11.50, a quick read on workforce productivity versus industry peers.

As of the close on October 22, 2026, Tvardi Therapeutics Inc.'s stock has declined approximately 80.00% over the past 52 weeks. The 50-day moving average sits at 1.31, while the 200-day moving average is 2.45.

Over the twelve months ended June 30, 2026, Tvardi Therapeutics Inc. generated - - in revenue and converted that into -22.81M in net income, yielding earnings per share of -2.43. EBITDA reached -23.73M, while operating income came in at -23.81M.

As of June 30, 2026, Tvardi Therapeutics Inc. holds 13.80M in cash and equivalents against 126,918.50 in total debt, resulting in a net debt position of -13.80M. Total book value stands at 7.34M, with working capital of 6.96M providing operational flexibility.

Tvardi Therapeutics Inc. produced -21.91M in operating cash flow over the twelve months ended June 30, 2026.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -143.29: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches 1.84, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Tvardi Therapeutics Inc. shareholders.

Tvardi Therapeutics Inc.'s most recent stock split took place on April 17, 2025 with a 3:1 split ratio.

As of June 30, 2026, Tvardi Therapeutics Inc. has an Altman Z-Score of -13.56, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.